Browsing Tag
hypertrophic cardiomyopathy
5 posts
Tenaya Therapeutics’ TN-201 gene therapy shows early success in treating MYBPC3 hypertrophic cardiomyopathy
Discover how Tenaya Therapeutics’ TN-201 gene therapy is showing early signs of transforming treatment for MYBPC3-associated HCM—read more on the trial details and outlook.
Sanofi strengthens cardiovascular portfolio with Aficamten rights in Greater China
Cytokinetics, Incorporated (NASDAQ: CYTK) saw its shares climb by 4.8% after announcing a landmark agreement with Sanofi (NASDAQ:…
Edgewise Therapeutics initiates EDG-7500 Phase 1 trial targeting cardiac diseases
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a biopharmaceutical company specializing in muscle diseases, announced the commencement of its Phase…
Viz.ai, Bristol Myers Squibb sign deal for AI algorithm and Viz HCM software
Viz.ai, an artificial intelligence (AI) powered health technology company, has signed a multi-year agreement with Bristol Myers Squibb…
Cytokinetics bags FDA breakthrough therapy status for aficamten in oHCM
Cytokinetics has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for aficamten for the…